Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJIH83)

• Drug Name: XmAb20717 Drug Info
• Synonyms: XmAb717

Indication

Disease Entry	ICD 11	Status	REF
Advanced malignancy	2A00-2F9Z	Phase 1	[1]
Breast cancer	2C60-2C65	Phase 1	[2]
Melanoma	2C30	Phase 1	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMJIH83

Molecule-Related Drug Atlas

Drug(s) Targeting Cytotoxic T-lymphocyte protein 4 (CTLA-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ipilimumab	DMJTIYK	Melanoma	2C30	Approved	[4]
Tremelimumab	DMOQ9H1	Hepatocellular carcinoma	2C12.02	Approved	[5]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[6]
AK04	DMU7K86	Actinic keratosis	EK90.0	Phase 3	[7]
AK104	DMXJ8Z4	Cervical cancer	2C77.0	Phase 2	[8]
Lorigerlimab	DM2E8Z5	Prostate cancer	2C82.0	Phase 2	[9]
Vudalimab	DMSEEI0	Prostate cancer	2C82.0	Phase 2	[10]
AGEN1884	DMAP5B4	Cervical cancer	2C77.0	Phase 1/2	[11]
BMS-986288	DMM10J4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[12]
MK-1308	DM25QKC	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[13]

Drug(s) Targeting Programmed cell death protein 1 (PD-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nivolumab	DMAB9QE	Melanoma	2C30	Approved	[14]
Tislelizumab	DMGVUO5	Hodgkin lymphoma	2B30	Approved	[15]
MK-3475	DMBYNW0	Melanoma	2C30	Approved	[14]
Pembrolizumab	DMFQEA6	Melanoma	2C30	Approved	[1]
Cemiplimab	DMKMJHE	Cutaneous squamous cell carcinoma	2C30	Approved	[16]
Retifanlimab	DMRKTCP	Neuroendocrine cancer	2B72.1	Approved	[11]
Sintilimab	DMGWR0C	Hodgkin lymphoma	2B30	Approved	[17]
Dostarlimab	DM78NWP	Endometrial cancer	2C76	Approved	[18]
Toripalimab	DMSGA6Z	Demodex blepharitis	1G07	Approved in China	[19]
PDR001	DM53J6B	Melanoma	2C30	Phase 3	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	TTI2S1D	CTLA4_HUMAN	Not Available	[3]
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Not Available	[3]

References

• [1] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [2] ClinicalTrials.gov (NCT03517488) A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2). U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of Xencor.
• [4] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
• [6] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [7] A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
• [8] Clinical pipeline report, company report or official report of Akeso Biopharma.
• [9] Clinical pipeline report, company report or official report of MacroGenics
• [10] Clinical pipeline report, company report or official report of Xencor
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Clinical pipeline report, company report or official report of CytomX Therapeutics.
• [13] Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
• [14] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [15] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
• [16] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [17] Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
• [18] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
• [19] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
• [20] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)